Drug delIvery system for enhanced targeting of glioblastoma multiforme (GBM)
| Reference number | |
| Coordinator | Uppsala universitet - Inst Immunologi, Genetik patologi |
| Funding from Vinnova | SEK 2 000 000 |
| Project duration | July 2020 - June 2024 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
** Denna text är maskinöversatt ** The goal of the RELIEF project has been to develop a specific and biocompatible "drug-delivery" system that can be made commercially available. For our purpose, the goal was to enable us to take our newly developed bio-surface coatings from laboratory production to GMP production.
Expected long term effects
** Denna text är maskinöversatt ** The final product (liposomes carrying the new coating) has been tested in vivo with favorable results. Both of the new coatings, fHep liposomes and PMPC liposomes, showed similar or better performance than PEG-coated liposomes. Since the same type of coating can be applied to living cells, we anticipate that the technology can be used in other areas, eg transplant medicine, and other types of ischemia/reperfusion injury.
Approach and implementation
** Denna text är maskinöversatt ** The cooperation between the 5 consortium members has worked excellently under the leadership of Dr Gero Leneweit (Abnoba) even though much of the work has been done during COVID19 period. The end result provides opportunities for extending the collaboration, something that is under planning. No funding though has yet been identified.